LIPOSARCOMA, DEDIFFERENTIATED
Clinical trials for LIPOSARCOMA, DEDIFFERENTIATED explained in plain language.
Never miss a new study
Get alerted when new LIPOSARCOMA, DEDIFFERENTIATED trials appear
Sign up with your email to follow new studies for LIPOSARCOMA, DEDIFFERENTIATED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in rare cancer fight
Disease control CompletedThis study tested a new oral drug, brigimadlin (BI 907828), against standard chemotherapy (doxorubicin) in 400 adults with advanced dedifferentiated liposarcoma, a rare cancer. Participants received either the pill or an infusion every 3 weeks. The main goal was to see if brigima…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy aims to stall rare Cancer's return
Disease control CompletedThis study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) can better control liposarcoma, a rare soft-tissue cancer. Ten adults whose tumors had stopped growing on trabectedin alone received the combination. The goal was to see if the combo c…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New pill shows promise for rare Fat-Cell cancer
Disease control CompletedThis study tested a new cancer pill, brigimadlin, in 138 adults with a rare type of fat-cell cancer called dedifferentiated liposarcoma. The pill works by blocking a protein that helps the cancer grow. Researchers checked how safe the drug is and whether it shrinks tumors. Partic…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 12, 2026 13:39 UTC